Participation in the REMAIN-1 pivotal study remains strong. Learn more about how we are targeting a root cause of obesity, and meeting the unmet need of weight maintenance, here: https://lnkd.in/e3kDQw52. *Revita is for investigational use only in the US under Federal law. #FractylForward #obesity
Director of Bariatric Research at Orlando Health - OHWSBSI 🇺🇸 Scientific Director of IRCAD india 🇮🇳 Head of Bariatric Endoscopy of Mohak Bariatric and Robotics 🇮🇳 Head of Bariatric Endoscopy at EOC 🇲🇽
We are happy to announce our first case in another FDA - IDE trial at Orlando Health Weight Loss and Bariatric Surgery Institute 🇺🇸 The Endoscopic Thermal Duodenal Mucosal Resurfacing (DMR) with Fractyl Health tech for the REMAIN trial in patients who have lost at least 15% total body weight on GLP-1 drug therapy and wish to discontinue their GLP-1 drug without weight regain. https://lnkd.in/eDNqsrQ3 Always led by Andre Teixeira MD, FACS, FASMBS with a #teamwork of Muhammad Ghanem MD, FACS, FASMBS, DABOM , Hany Takla, MD , FACS, FASMBS , Muhammad Jawad, Alexis Sanchez MD MS MBA , Leticia Morales and Manoel Galvao Neto I am pleased and honored to circle it back since we did the First-in-human case series more than 10y ago in 2013 with Leonardo Rodriguez Grunert in Chile 🇨🇱 https://lnkd.in/e4ZZqNe6 Jay Caplan, thank you for your support and trust in our team.
Congratulations!
Healthcare consultant | Certified Quality Management Auditor 9001:2015 | MBBS | Medical Billing Consultant
1wCongratulations team ..... it is beautiful seeing the actual prob in.